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A Ab bs st tr ra ac ct t
Inherited breast-ovarian cancer was described in 1866. The underlying genetic defects in BRCA1/2 were
demonstrated 128 years later. We now have 10 years of experience with genetic testing in BRCA kindreds.
The majority of breast cancer kindreds (familial breast cancer) do not demonstrate ovarian cancer and are
not associated with BRCA mutations. The effect of early diagnosis and treatment is monitored through
international collaborations. 
BRCA1-associated breast cancer is biologically different from other breast cancers, including a worse prognosis.
BRCA2-associated breast cancer is, beside early onset, in many ways similar to sporadic breast cancer.
Mammography screening of the high risk groups aiming at early diagnosis and treatment, seems promising for
familial breast cancer and for BRCA2-associated breast cancer, but numbers included for BRCA2 carriers are
limited. BRCA1-carriers have worse prognosis, and the potential benefit of MRI for early diagnosis is now being
explored. Early diagnosis and treatment of ovarian cancer does not substantially improve survival, and prophylactic
oophorectomy at the end of childbearing ages is advocated. Prophylactic mastectomy is debated, and we may
await the results of MRI trials before recommending this option. Familial breast cancer and BRCA2-associated
breast cancers are often oestrogen receptor positive, and may be prevented by oestrogen blockers/inhibitors.
Oophorectomy prevents ovarian cancer, and may possibly prevent both receptor positive and receptor negative
breast cancer as well, also while using HRT. Oral contraceptives may reduce ovarian cancer risk and increase
breast cancer risk, irrespective of initial risk and genetic subgroup.
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Inherited  breast  cancers  are  (pleiotropic)
expressions of mutations in a number of distinct genes
causing other cancers as well. To some extent, the
biological function of the different genes is known, and
to some extent the ways breast cancers are produced
when this function is lacking, have been described. The
different genetic causes lead to biologically different
diseases. The cancers associated with different genetic
syndromes occur at different ages, they may differ with
respect to tumour characteristics, they have different
prognosis, and they respond differently to prophylactic
and treatment modalities. Following the clinical genetic
work-up to provide health care to a woman possibly
at risk for inherited breast cancer, there is a multistep
approach. If she is demonstrated to be at risk, the
preventive/treatment  modalities  she  needs  are
a consequence of which subgroup of the inherited
breast cancers she is at risk with. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 12
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In most European countries, it is the understanding
to discuss health care as what is to be offered to any
woman who needs it. Thus, the question is not what
might be done or what money possibly can buy – it is
about what is reasonable and affordable. It is also
about tradition and culture – what is possible in the
current socio-ethical context. This contribution relates
to these bearings. 
The first detailed scientific description of inherited
breast-ovarian cancer was given by Paul Broca in 1866
[1]. He demonstrated the transmission of the assumed
underlying genetic defect, its expressions, the age-related
and sex-limited penetrance, and the possibilities of
modifying environmental and genetic factors. Not until
10 years ago, we learned that the syndrome is produced
by BRCA1 mutations. BRCA2 mutations produce breast
cancers in a similar prevalence and at a similar age, but
with completely different tumour characteristics and with
a different set of associated cancers. A number of
additional genes cause multiorgan cancer syndromes
when mutated, including mutations in TP53, PTEN, ATM
and CHEK2. Germline mutations in TP53 and PTEN
invoke childhood cancers. Heterozygous state for ATM
mutation as a predisposition to breast cancer is debated,
and the CHEK2 syndrome needs further evaluation.
These rare genetic syndromes are not further discussed
in this paper. 
Some [2] assume that there have to be more
dominantly inherited breast cancer genes, others
disagree and conclude that they may be recessive, low
penetrant  or  multifactorially  interacting,  but  not
dominantly inherited with high penetrance [3]. All
cancer genetic clinics are aware that “inherited breast
cancer” outside demonstrated BRCA mutation carrying
syndromes may be a fiction, nevertheless all such clinics
have defined a large volume of “inherited breast
cancer” cases defined by family history but lacking
demonstrated DNA mutations and referred them to
follow-up  examinations.  We  have  demonstrated
a BRCA mutation in but a small fraction of our at-risk
families, and we have excluded BRCA mutations in
a number of large dominantly inherited breast cancer
pedigrees. There are genes not yet found. 
None of the models for probability calculations for
recurrence risk of breast cancer in breast cancer kindreds
are valid after a BRCA mutation have been excluded –
they all assume that the patient is selected from an
untested population. However, many cancer genetic
centres continue to estimate the probability that a given
woman is a mutation carrier, after she has been tested
and found not to be so. This makes sense if you – as we
do – believe there are more genes. It does not make
sense if you do not believe so. Whatever we may believe,
the calculations are wrong, because they cannot be
interpreted without correcting the probability estimates
for the testing performed prior to the calculations.
Moreover,  our  activity  of  nesting  up  all  the  large
mutation-carrying families will remove a substantial part
of the mutation carriers from the population before the
remaining familial clusters are referred to genetic
counselling: for each passing day, the next familial cluster
of breast cancer referred is less likely to harbour one of
our founder BRCA1 mutations. 
Several reports have estimated penetrance of BRCA
mutations with respect to breast cancer. The results differ
widely. This may in principle be due to four factors: (1)
selection biases, (2) improper algorithms to calculate
penetrances, (3) true differences between the mutations
examined and/or (4) environmental or genetic modifiers
of penetrance. Because the first series obviously had
selection biases and because many of the families were
not tested (carrier status for relatives was assumed,
calculated upon and thereafter presented as results),
the methodological problems may have been major.
Studies based upon testing rather than assuming carrier
status, and studies employing sophisticated statistics to
eliminate methodological problems, now agree that
penetrance for breast cancer is high for all BRCA1 or
BRCA2 truncating mutations [4-5]. 
Breast and ovarian cancers are competitive causes
of death in a BRCA1/2 mutation carrier, and both are
caused by the same mutation. Estimating the penetrance
of  breast  cancer  (or  ovarian  cancer)  implies  the
methodological  problem  of  informed  censoring:
whatever you do is methodologically wrong, because
you censor the data with an argument dependent on
what you are examining. Because there is no universally
“correct” method, the solution is to formulate explicit
questions specifying the assumptions to the answers. 
If a figure for probability for a healthy mutation carrier
to contract ovarian cancer is looked for, one must
censor out all mutation carriers when they contract
another (breast) cancer. Doing so, lifetime penetrance
for ovarian cancer is high in BRCA1 mutation carriers,
possibly as high as for breast cancer. Two of the reasons
for the low penetrance for ovarian cancer in some
studies may be the combined effect that the families
were selected for by the presence of breast cancer, and
the fact that you may not contract ovarian cancer after
having died of breast cancer. In addition, there may be
biological differences between different mutations in theH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 13
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same genes. The exercise of pooling a number of small
families without excluding the index cases used to
ascertain the families, with different mutations, without
actually testing the relatives but assuming their carrier
status, without specifying the questions addressed and
how the data are censored to answer that question, may
give results of low practical value. 
A  statistical  flaw  has  made  some  mistakenly
conclude  that  BRCA1-associated  cancers  have
prognosis similar to other breast cancers. The flaw is
that according to oncological standards for randomized
trials to evaluate effects of treatment modalities, the
BRCA1 cancers have been compared to controls
selected for similar prognostic tumour characteristics
(oestrogen receptor, histopathological grade, etc.). In
this way, BRCA1 cancers have been matched with
a subset  of  patients  demonstrated  to  have  bad
prognostic signs (over-parameterization). The question
of whether BRCA1 mutation carriers have even worse
prognosis is debated, but all studies agree that BRCA1
cancers have worse prognosis than age-matched
controls [6-7]. Because a germline mutation is always
prior to the tumour it causes, it is not meaningful to have
the  opposite  as  an  alternative.  However,  most
microarray  studies  present  hierarchical  trees  with
germline  mutations  as  late  events.  Possibly,  the
mathematical models are pertinent, but the way the
results  are  presented  may  seduce  the  readers  to
conceptional misunderstandings. 
BRCA1-associated breast cancers are, as a group,
different from all other defined groups of breast cancers
[6-8]. The picture is so clear that all exceptions may be
sporadic cancers caused by different mechanisms in
BRCA1 mutations carriers (age-related sporadic breast
cancer may occur in BRCA1 mutation carriers as well).
The BRCA1-associated breast cancers are hormone
receptor negative, of histopathological high grade, and
they are close to never appear as precancers (DCIS)
when diagnosed clinically or by mammography. Attempts
of early diagnosis to achieve early treatment was initially
considered successful: the tumours diagnosed were small
and often without spread. It turned out, however, that
the prognosis was not as good as hoped for according
to the stage at diagnosis: retrospective series before any
attempt on early diagnosis and treatment demonstrated
5-year survival of 63% for invasive BRCA1 cancers [9].
The results of the Biomed2 prospective series included
a 5-year survival of 63% for invasive BRCA1 cancers,
point estimate was no effect at all [7]. The conclusion
was  that  annual  clinical  mammography  for  early
detection did not work. Prophylactic mastectomy is an
alternative [10-11], but with severe implications both on
personal and professional ethical levels, and it is resource
demanding. A new attempt on secondary prophylaxis
has been implemented in most centres: MRI obviously
has the capability of demonstrating tumours invisible in
mammography [12]. We do not, however, at present
know whether or not MRI may diagnose the tumours
before  they  have  biologically  achieved  their  bad
prognostic propensities. We hope it will work. All our
BRCA1 mutation carriers are now subjected to annual
MRI. Shortly we will have the early figure for their 5-year
survival. We ask for time-out to retrieve this figure before
we consider the alternatives. 
Early diagnosis and treatment to improve prognosis
for  inherited  ovarian  cancer  was  undertaken  by
ultrasound and CEA125 in many centres. It did not work
– no report claims substantial improvement in survival
[13]. Actually, there are few reports on survival, most
reports mention cancer with spread at diagnosis but
give no survival data. However, it became clear that
BRCA1-associated ovarian cancer seldom occurs before
the  age  of  40.  Combined  with  the  finding  that
oophorectomy at that age reduced not only ovarian
cancer risk by more than 90%, but also reduced breast
cancer risk in BRCA1 mutation carriers – even in those
using hormone replacement therapy [14] – most centres
advocate prophylactic oophorectomy past childbearing
ages [15]. In contrast to prophylactic mastectomy where
uptake is low, the majority of postmenopausal BRCA1
carriers seem to choose oophorectomy. If a mean to
early diagnosis and cure for ovarian cancer appears,
we may soon have no BRCA1 carriers left to evaluate
the effects, because there may not be many ovaries left
in the mutation carriers aged over 40 years. Moreover,
the disease is so lethal and prophylactic oophorectomy
past childbearing ages seems to be so well tolerated,
that it would be hard to suggest a trial. In contrast to
the differences in breast cancer phenotype, ovarian
cancer caused by BRCA2 seems similar to that caused
by BRCA1, besides that the penetrance may be lower
and disease onset later in BRCA2 carriers. 
One  report  concluded  that  oophorectomy  in
BRCA1  carriers  contracting  cancer  improved  the
prognosis of the breast cancer [7]. This observation
needs to be supported by an independent series, but
it is in keeping with the beneficial effect of prophylactic
oophorectomy to breast cancer risk in the same group. 
Breast cancers in inherited/familial non-BRCA1/2
carriers have good prognosis (about 90% 5-year
survival) inside early detection programmes applyingH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 14
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annual  clinical  mammography  [7].  Moreover,
a number of cases are demonstrated as precancers
(DCIS), and they have reportedly 100% event-free 5-
year survival. Few studies have been presented on
prospective  survival  in  BRCA2-associated  breast
cancers, but these cancers seem to be comparable to
sporadic breast cancers beside the young age of onset
[8]. There is no indication that the prognosis should
be worse than that of non-BRCA1/2-associated breast
cancers. 
Because all non-BRCA1 carriers (including the
BRCA2  carriers)  predominantly  contract  hormone
receptor-positive breast cancers, they should theoretically
benefit from receptor blocking agents (like tamoxifen)
and oestrogen production blocking agents (aromatase
inhibitors). All available evidence indicate so. Most agree
that by now it would be reasonable to suggest such
chemoprevention to these groups, but there is no
agreement on which compound and exactly which group
to address. It is advocated to give various regimens of
such treatment under strict control to evaluate the effects.
That is where we are today: trials and discussions, but
no consensus on applying chemoprevention as standard
health care. 
Again, the BRCA1-associated cancers differ. It may
be expected that because as a group they have
receptor-negative cancers, they should not respond
either to oestrogen blockers or to oestrogen. Neither
is true. In BRCA1 carriers, oophorectomy prevents
breast cancer [14], tamoxifen prevents contralateral
breast cancer [16], and oral contraceptives induce
breast cancer [17]. Why and how is unclear. It seems,
however, irrational to suggest oestrogen blockers to
prevent oestrogen receptor-negative tumours. 
In oncology, the scientific standard is a randomized
trial.  As  is  evident  from  the  reports  (beside
chemoprevention)  mentioned  above,  we  have  no
randomized trials. You cannot randomize a woman to
mastectomy, and you cannot deprive a mutation-carrying
woman from any potential life-saving health care
available. We are faced with the challenge of doing
science without randomized trials, and we cannot (as
the mammographic screening of older women) go and
get the families we want for research. This leaves us with
series subjected to a number of ascertainment biases,
and we should interpret the results with caution. Because
we are outside the framework of randomized trials, we
may be better off not discussing exact figures in single
reports, but rather focus on the main results, methods
employed and whether or not the empirical facts are in
keeping with the current paradigms for understanding.
In  this  perspective,  it  may  seem  that  we  need  to
reconsider our paradigms for BRCA1-associated breast
cancer. For the other groups, early diagnosis and
treatment works as expected, improving early diagnosis
may hopefully further improve the results obtained so
far, and the principles of chemoprevention may be
projected from sporadic cancers. 
In conclusion to the facts discussed above, most
clinical genetic centres relating to inherited breast
cancer today advocate annual mammography from the
age of 30 onwards to women at risk for inherited
non-BRCA1 breast cancer. It is agreed that besides
BRCA1  carriers,  oestrogen  blockers/aromatase
inhibitors may be beneficial – but there is no agreement
on exactly how to implement such chemoprevention. 
In contrast, annual mammography does not work
in BRCA1 carriers. We are now hoping MRI to be
better  to  avoid  large  numbers  of  prophylactic
mastectomies. We are confused by the data on the
effect of hormones and hormone blockers in BRCA1
carriers, and we all hope for chemoprevention to
make  the  unpleasant  discussion  of  prophylactic
surgery superfluous if early detection and treatment
does not work. Early diagnosis does not work for
ovarian cancers, but oophorectomy is beneficial and
advocated at the end of childbearing ages. 
T Ta ab bl le e   1 1. .   P Pr ri im ma ar ry y   a an nd d   s se ec co on nd da ar ry y   p pr re ev ve en nt ti io on n   f fo or r   w wo om me en n   a at t   r ri is sk k   f fo or r
i in nh he er ri it te ed d   b br re ea as st t   o or r   b br re ea as st t- -o ov va ar ri ia an n   c ca an nc ce er r
B BR RC CA A1 1   m mu ut ta at ti io on n   c ca ar rr ri ie er rs s   ( (b by y   t te es st ti in ng g   o or r   a as ss su um me ed d   b by y   f fa am mi il ly y   h hi is st to or ry y) )   
1. Annual clinical mammography and MRI from the age of 30 
years onwards. For demonstrated mutation carriers there 
should be no upper age limit. Healthy at-risk women based 
on family history alone will have low probability for being 
mutation carriers over 70 years of age. 
2. Prophylactic mastectomy should be an option, but may not 
be actively advocated until the benefit of MRI is known. 
3. Prophylactic oophorectomy over 35 years of age when 
family is completed. 
B BR RC CA A2 2   m mu ut ta at ti io on n   c ca ar rr ri ie er rs s   ( (b by y   t te es st ti in ng g   o or r   a as ss su um me ed d   b by y   f fa am mi il ly y   h hi is st to or ry y) )   
1. As for BRCA1 mutation carriers, but oophorectomy may 
not be indicated before 40 years of age. 
2. There is no consensus on practical use, but anti-oestrogens 
may prevent oestrogen receptor-positive tumours. 
F Fa am mi il li ia al l   b br re ea as st t   c ca an nc ce er r   ( (h hi ig gh h   b br re ea as st t   c ca an nc ce er r   r ri is sk k   a ac cc co or rd di in ng g   t to o   f fa am mi il ly y   
h hi is st to or ry y   n no ot t   i in nc cl lu ud di in ng g   o ov va ar ri ia an n   c ca an nc ce er r) )   
1. Annual clinical mammography from the age of 30 years 
onwards. 
2. There is no consensus on practical use, but anti-oestrogens 
may prevent oestrogen receptor-positive tumours. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 15
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As is the case with most scientific reports, this
contribution  has  focused  on  unsolved  problems. 
We may remember, however, that we actually have
about 90% 5-year survival of non-BRCA1 breast cancer
with today’s means [7], and the great majority of
inherited  breast  cancers  belong  to  this  group.
Prophylactic oophorectomy at the end of childbearing
ages in BRCA1 carriers reduces morbidity and mortality
by more than 50% [14]. The systematic attempts to
prevent and cure inherited breast cancer have been
undertaken for but about 10 years. The results are
actually good, which is reflected in the high compliance
from the affected kindreds [18]. The attempts to prevent
and cure inherited breast cancer is an example of
a consumer-driven activity based on knowledge and
collaboration from the patients needing our care.
Actually, based on knowledge two BRCA1 carriers with
small invasive tumours without spread this year have
asked me for immediate chemotherapy. Educated
patients may soon be our scientific collaborative
partners. Trials we cannot impose upon them, may
soon be initiated by patients who want to know. 
The physicians and the researchers have the role of
producing,  filing,  retrieving  and  communicating
knowledge as appropriate. The choice what to do,
however, should be the patient’s choice, there are no
scientific arguments as to whether or not to undergo
prophylactic oophorectomy. As we all know, there are
more arguments about what to do with your life than
the doctors’ suggestions. The high compliance to our
advice during the last decade most probably reflects
that the families have identified their problems long ago
and were waiting for our care. The high compliance to
genetic testing obviously reflects the opinion that our
activity may prevent and cure. To maintain the high
compliance, we should not over-sell expected results of
interventions. We do not need to gain trust, we already
have it. But we may lose it. Our role is not to make
decisions. It is our obligation, however, to ensure that
the advocated options are actually available to each
single patient. In addition, we may produce arguments
to  advocate  some  options  because  they  have
consequences to our liking. The suggestions in Table
1 may be agreed by most, and some would go further
and actively advocate prophylactic mastectomy in
BRCA1 carriers and chemoprevention for the rest.
Genetic counselling is to present information and
options so that any given patient may be supported in
exploring her values to make her choices. The challenge
is to support the patients who make choices not
corresponding with your own priorities. 
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